Ind-Swift Laboratories Limited (INDSWFTLAB)
ISIN: - Industry: Drug Manufacturers—Specialty & Generic Sector: Healthcare Website
64
-0.25(-0.39%)

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and advanced intermediates in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, and antineoplastic, as well as various products for ADHD symptoms. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company also exports its products. The company was incorporated in 1995 and is headquartered in Manimajra, India.

Pricing Updates

TODAY'S HIGH

64.3

TODAY'S LOW

63.7

52 WEEK HIGH

89.9

52 WEEK LOW

52.65

Major Holders

% of Shares Held by
All Insider

68.23%

% of Shares Held by
Institutions

0.00%

% of Float Held by
Institutions

0.00%

Number of Institutions
Holding Shares

0

Company Overview

MARKET CAP

378.15 Cr.

ETERPRISE VALUE

1283.27 Cr.

NO. OF SHARES

5.90 Cr.

BOOK VALUE

109.386

DIV. YIELD

1%

DEBT

916.23 Cr.

GROSS PROFIT

525.53 Cr.

CASH

13.86 Cr.

REVENUE

1157.05 Cr.

REVENUE/SHARE

195.831

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Investments17.12 Cr.-6.28 Cr.1.10 Cr.-24.72 Lakhs
Change To Liabilities0000
Total cashflows from Investing Activities4.77 Cr.-10.17 Cr.-9.09 Cr.-12.46 Cr.
Net Borrowings-36.01 Cr.-39.85 Cr.-65.74 Cr.161.29 Cr.
Total Cash from Financing Activities-140.87 Cr.-123.74 Cr.-133.25 Cr.99.62 Cr.
Other Liabilities-8.90 Cr.8.25 Cr.33.59 Cr.-221.37 Cr.
Total Assets00052 Lakhs
Net Income-2.14 Cr.-3.14 Cr.-21.18 Cr.28.94 Cr.
Change in Cash14.16 Cr.1.02 Cr.-17.11 Cr.22.75 Cr.
Effect of Exchange Rate0000
Total Cash from Operating Activities150.27 Cr.134.94 Cr.125.23 Cr.-64.39 Cr.
Depreciation131.03 Cr.55.16 Cr.90.05 Cr.104.04 Cr.
Other Cashflows from Investing Activities56.21 Lakhs51.28 Lakhs58.72 Lakhs2.70 Cr.
Dividends Paid0000
Change to Inventory-52.83 Cr.-32.84 Cr.-26.20 Cr.-6.56 Cr.
Change to Account Receivables-26.17 Cr.-38.45 Cr.-38.39 Cr.13.13 Cr.
Other Cashflows from Financing Activities-104.86 Cr.-83.89 Cr.-67.51 Cr.-62.19 Cr.
Change to Net Income109.30 Cr.113.21 Cr.87.37 Cr.20 Cr.
Capital Expenditures-18.41 Cr.-3.91 Cr.-10.74 Cr.-15.25 Cr.

Financials

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax12.53 Cr.18 Cr.-19.77 Cr.49.67 Cr.
Minority Interest-11.02 Lakhs-8.97 Lakhs-8.97 Lakhs-8.97 Lakhs
Net Income108.06 Cr.110.95 Cr.73.95 Cr.44.48 Cr.
Selling General Administrative114.35 Cr.107.85 Cr.105.84 Cr.101.80 Cr.
Gross Profit554.85 Cr.455.32 Cr.402.68 Cr.375.65 Cr.
Ebit108.06 Cr.110.95 Cr.73.95 Cr.44.48 Cr.
Operating Income108.06 Cr.110.95 Cr.73.95 Cr.44.48 Cr.
Other Operating Expenses201.40 Cr.149.22 Cr.132.82 Cr.125.31 Cr.
Interest Expense-95.53 Cr.-93.35 Cr.-102.46 Cr.-83.95 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense14.68 Cr.21.15 Cr.1.41 Cr.20.73 Cr.
Total Revenue1081.44 Cr.906.77 Cr.799.34 Cr.779.01 Cr.
Total Operating Expenses973.38 Cr.795.81 Cr.725.38 Cr.734.52 Cr.
Cost of Revenue526.58 Cr.451.44 Cr.396.66 Cr.403.36 Cr.
Total Other Income Expense Net-95.53 Cr.-92.95 Cr.-93.73 Cr.5.18 Cr.
Discontinued OperationsNoneNoneNoneNone
Net Income from Continuous Ops.-2.14 Cr.-3.14 Cr.-21.18 Cr.28.94 Cr.
Net Income Applicable to Common Shares-2.14 Cr.-3.14 Cr.-21.18 Cr.28.94 Cr.

Balance Sheet

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Intangible Assets1.03 Cr.9.20 Cr.40.84 Cr.75.93 Cr.
Capital Surplus0307.31 Cr.307.31 Cr.243.38 Cr.
Total Liabilities1199.96 Cr.1215.03 Cr.1229.37 Cr.1336.14 Cr.
Stock Holder Equity600.97 Cr.603.50 Cr.640.63 Cr.587.81 Cr.
Minority Interest-11.02 Lakhs-8.97 Lakhs00
Other Liabilities53.82 Cr.34.60 Cr.28.10 Cr.30.13 Cr.
Total Assets1800.82 Cr.1818.44 Cr.1870 Cr.1923.96 Cr.
Common Stock59.80 Cr.59.08 Cr.59.08 Cr.47.56 Cr.
Retained Earnings061.34 Cr.49.24 Cr.57.18 Cr.
Other Liabilities17.17 Cr.15.90 Cr.14.95 Cr.14.56 Cr.
Good Will021.13 Lakhs21.13 Lakhs21.13 Lakhs
Treasury Stock541.16 Cr.175.76 Cr.224.99 Cr.239.66 Cr.
Other Assets57.51 Cr.81.24 Cr.149.98 Cr.146.43 Cr.
Cash21.47 Cr.11.60 Cr.10.58 Cr.29.96 Cr.
Current Liabilities334.50 Cr.314.52 Cr.323.06 Cr.356 Cr.
Long Term Asset Charges51.89 Cr.60.35 Cr.77.97 Cr.78.82 Cr.
Short Long Term Debt047.98 Cr.57.01 Cr.90.11 Cr.
Other Stockholder Equity541.16 Cr.175.76 Cr.224.99 Cr.239.66 Cr.
Property Plant Equipment636.83 Cr.748.08 Cr.798.49 Cr.844.92 Cr.
Total Cur. Assets1076.38 Cr.944.18 Cr.863.02 Cr.836.08 Cr.
Long Term Investments29.06 Cr.35.52 Cr.17.45 Cr.20.36 Cr.
Net Tangible Assets599.93 Cr.594.09 Cr.599.58 Cr.511.66 Cr.
Short Term Investments0000
Net Receivables454.78 Cr.478.23 Cr.420.51 Cr.371.79 Cr.
Long Term Debt847.78 Cr.884.12 Cr.890.88 Cr.965.57 Cr.
Inventory428.50 Cr.375.66 Cr.342.81 Cr.316.60 Cr.
Accounts Payable175.95 Cr.138.82 Cr.135.22 Cr.126.67 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account